206 related articles for article (PubMed ID: 1729617)
1. Treatment of postmenopausal osteoporosis with calcitriol or calcium.
Tilyard MW; Spears GF; Thomson J; Dovey S
N Engl J Med; 1992 Feb; 326(6):357-62. PubMed ID: 1729617
[TBL] [Abstract][Full Text] [Related]
2. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
[TBL] [Abstract][Full Text] [Related]
3. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
Watts NB; Harris ST; Genant HK; Wasnich RD; Miller PD; Jackson RD; Licata AA; Ross P; Woodson GC; Yanover MJ
N Engl J Med; 1990 Jul; 323(2):73-9. PubMed ID: 2113611
[TBL] [Abstract][Full Text] [Related]
4. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
McCloskey E; Selby P; Davies M; Robinson J; Francis RM; Adams J; Kayan K; Beneton M; Jalava T; Pylkkänen L; Kenraali J; Aropuu S; Kanis JA
J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495
[TBL] [Abstract][Full Text] [Related]
5. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.
Riggs BL; Hodgson SF; O'Fallon WM; Chao EY; Wahner HW; Muhs JM; Cedel SL; Melton LJ
N Engl J Med; 1990 Mar; 322(12):802-9. PubMed ID: 2407957
[TBL] [Abstract][Full Text] [Related]
6. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.
Storm T; Thamsborg G; Steiniche T; Genant HK; Sørensen OH
N Engl J Med; 1990 May; 322(18):1265-71. PubMed ID: 2109197
[TBL] [Abstract][Full Text] [Related]
7. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin.
Sambrook P; Birmingham J; Kelly P; Kempler S; Nguyen T; Pocock N; Eisman J
N Engl J Med; 1993 Jun; 328(24):1747-52. PubMed ID: 7684512
[TBL] [Abstract][Full Text] [Related]
8. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
Neer RM; Arnaud CD; Zanchetta JR; Prince R; Gaich GA; Reginster JY; Hodsman AB; Eriksen EF; Ish-Shalom S; Genant HK; Wang O; Mitlak BH
N Engl J Med; 2001 May; 344(19):1434-41. PubMed ID: 11346808
[TBL] [Abstract][Full Text] [Related]
9. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
Ensrud KE; Black DM; Palermo L; Bauer DC; Barrett-Connor E; Quandt SA; Thompson DE; Karpf DB
Arch Intern Med; 1997 Dec 8-22; 157(22):2617-24. PubMed ID: 9531231
[TBL] [Abstract][Full Text] [Related]
10. The antifracture efficacy of alendronate.
Seeman E
Int J Clin Pract Suppl; 1999 Apr; 101():40-5. PubMed ID: 12675021
[TBL] [Abstract][Full Text] [Related]
11. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older.
Seeman E; Vellas B; Benhamou C; Aquino JP; Semler J; Kaufman JM; Hoszowski K; Varela AR; Fiore C; Brixen K; Reginster JY; Boonen S
J Bone Miner Res; 2006 Jul; 21(7):1113-20. PubMed ID: 16813532
[TBL] [Abstract][Full Text] [Related]
12. Effects of treatments by calcium and sex hormones on vertebral fracturing in osteoporosis.
Almustafa M; Doyle FH; Gutteridge DH; Hand DJ; Davis TM; Spinks TJ; Freemantle C; Joplin GF
Q J Med; 1992 Apr; 83(300):283-94. PubMed ID: 1321457
[TBL] [Abstract][Full Text] [Related]
13. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
[TBL] [Abstract][Full Text] [Related]
14. Calcitriol and alendronate combination treatment in menopausal women with low bone mass.
Malavolta N; Zanardi M; Veronesi M; Ripamonti C; Gnudi S
Int J Tissue React; 1999; 21(2):51-9. PubMed ID: 10568224
[TBL] [Abstract][Full Text] [Related]
15. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis.
Silverman SL; Delmas PD; Kulkarni PM; Stock JL; Wong M; Plouffe L
J Am Geriatr Soc; 2004 Sep; 52(9):1543-8. PubMed ID: 15341559
[TBL] [Abstract][Full Text] [Related]
16. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
Kanis JA; Johansson H; Oden A; McCloskey EV
Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
[TBL] [Abstract][Full Text] [Related]
17. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
Seeman E
Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
[TBL] [Abstract][Full Text] [Related]
18. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
Lindsay R; Scheele WH; Neer R; Pohl G; Adami S; Mautalen C; Reginster JY; Stepan JJ; Myers SL; Mitlak BH
Arch Intern Med; 2004 Oct; 164(18):2024-30. PubMed ID: 15477438
[TBL] [Abstract][Full Text] [Related]
19. Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind, double placebo study.
Ebeling PR; Wark JD; Yeung S; Poon C; Salehi N; Nicholson GC; Kotowicz MA
J Clin Endocrinol Metab; 2001 Sep; 86(9):4098-103. PubMed ID: 11549632
[TBL] [Abstract][Full Text] [Related]
20. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women.
Dawson-Hughes B; Dallal GE; Krall EA; Sadowski L; Sahyoun N; Tannenbaum S
N Engl J Med; 1990 Sep; 323(13):878-83. PubMed ID: 2203964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
